• Vitrue Health

  Participated · Equity · Feb 2024

  Vitrue Health operates a digital musculoskeletal (MSK) health platform for workplaces that uses computer vision and biomechanical analysis to deliver workplace health assessments that are accurate, holistic and personalised. The platform aims to reduce musculoskeletal pain and help employers fulfil regulatory obligations at scale. It is used by customers including Bupa, the NHS, Hastings Direct and Campari. Led by CEO Shane Lowe, the London-based technology startup specialises in reducing musculoskeletal pain and supporting workplace health. The company raised $4M in a recent funding round, bringing its total funding to $7M. Vitrue plans to use the proceeds to grow the team and advance expansion across the US and into new European markets.

• Collective Minds Radiology

  Led · Equity · Aug 2023

  Collective Minds Radiology builds a cloud-based collaboration platform for healthcare that provides access to data as well as human and digital expertise for clinical consultation, education, and research. The company offers products and services focused on medical imaging research, clinical consultation, and education. Founded in 2017 and led by CEO Andre Nordell, the Stockholm-based health-tech startup has connected over 14,000 healthcare professionals and 170 healthcare providers and hospitals to its platform. In August 2023 it closed SEK84M (approx. USD7.615M) in financing. The company intends to use the proceeds to accelerate commercial expansion of its professional healthcare collaboration platform. No other financial details were disclosed in the article. Collective Minds Radiology develops a cloud‑based healthcare collaboration service that enables doctors, researchers and industry to collaborate across borders on medical imaging, consultations, clinical trials and education. The platform today connects 50 hospitals and more than 2,000 doctors. The company says demand has grown during the pandemic as hospitals and specialists seek better digital collaboration. Collective Minds has commercial and clinical management in Stockholm and product development in Barcelona. The recently raised capital will support continued technology development, expansion of the team, further European expansion and preparations for a global launch. The company positions itself as building a network of collective and artificial intelligence in radiology to improve diagnosis and clinical research.

• Gleamer

  Participated · Series B · Jun 2023

  Gleamer is a French med-tech company that builds artificial-intelligence tools to augment radiologists’ workflows. Its flagship platform, Gleamer Copilot, uses computer vision models to detect and quantify abnormalities on imaging studies. The company’s next product line, “OncoView,” will apply the same AI technology to oncology CT scans, initially targeting lung and bone metastases and later expanding to broader cancer imaging needs. Gleamer plans to invest €18 million over the next five years to develop a full suite of applications for lesion detection, measurement, and treatment-response monitoring. The project is being executed in partnership with leading French healthcare institutions and industrial collaborators, and is supported by a dedicated R&D team specializing in AI, data science, and clinical research. A €4.5 million government co-funding award under France’s “Digital Health” initiative will partially finance the effort, underscoring national recognition of the company’s technology and market leadership. Although operating metrics such as revenue or user count were not disclosed, management positions the company as a global leader in AI for medical imaging.

• Surgery Hero

  Participated · Seed · Nov 2022

  Surgery Hero (formerly Sapien Health Limited) is a London‑headquartered digital clinic delivering personalised pre‑ and post‑operative programmes via the Surgery Hero app. Members receive programmes tailored to their individual surgical risk factors and are paired with an expert human health coach to turn guidance into action. The company is currently commissioned by 10% of Integrated Care Systems in the UK and is committed to providing over 8,000 programmes to people awaiting surgery. A collaboration with South Tees Hospitals NHS Foundation Trust found programme participants had an average hospital stay one day shorter, representing a £273 cost saving per patient. Founded in May 2020, Surgery Hero plans to scale its solution using machine learning and to establish a foothold in the US market. The business has seen increased demand driven by growing surgical waiting lists related to the COVID‑19 pandemic and has a stated mission to help 100 million people have successful surgery.

• CardiaTec Biosciences

  Participated · Seed · Jul 2022

  CardiaTec is a Cambridge University spinout that applies AI and multi-omics analysis to discover novel treatments for cardiovascular disease. The company aggregates human heart tissue data from 65 hospitals across the U.K. and the U.S. to build what it calls the largest human heart tissue multi-omics dataset. Its platform integrates genetics, epigenetics, gene expression, and protein data to identify disease mechanisms and therapeutic targets. CardiaTec was founded in 2021 and is led by CEO Raphael Peralta, COO Thelma Zablocki, and CTO Namshik Han. With an eight-person team in Cambridge, the company plans wet-lab validation of targets and to begin identifying and testing drug candidates over the coming years. Financially, CardiaTec had previously raised $1.8 million in pre-seed funding and has just completed a new seed round to fund data collection and validation work. CardiaTec Biosciences develops a proprietary AI-driven target discovery platform that analyzes large-scale multiomic cardiovascular data. Its platform links gene variation, methylation, expression, proteomic and metabolomic signals to reveal systems-level relationships in disease. The company aims to accelerate drug discovery, reduce costs, and deliver new compounds to help patients. CardiaTec was founded in 2021 by Raphael Peralta, Thelma Zablocki, and Dr. Namshik Han and is based in Cambridge, MA. In July 2022 it raised £1.4M in a pre-seed round to fund continued development. The funds will be used to advance the platform and unearth new treatments for cardiovascular patients.

No current team members are available.